Share the latest information
A leading global enterprise in the research and development of innovative single domain antibody (sdAb) drugs
Recently, Dr. Yakun Wan, founder and chairman of Shanghai Novamab Biopharmaceuticals Co., Ltd., was invited to participate in the 2023 American Thoracic Society International Conference and the 2023 BIO International Convention.
ATS 2023 will be held in Washington D.C., USA from May 19th to 24th, 2023. Dr. Wan Yakun will present three themed posters at booths P94, P95, and P96 on May 21, 2023 from 9:00 to 16:15 (local time):
（1）Phase I Safety and Efficacy Evaluation of the First-in-class lnhalable Anti-lL-4Ra Single Domain Antibody；
（2）First-in-class lnhalable Anti-TSLP Single Domain Antibody With Therapeutic Potential in Asthma Treatment；
（3）First-in-class lnhalable Anti-notch2 Single Domain Antibody for the Treatment of Cystic Fibrosis Lung Disease。
The BIO International Convention 2023 will be held in Boston, USA from June 5-8, 2023. Dr. Yakun Wan will give a presentation on the theme "Innovative inhalable single domain anti body for respiratory diseases treatment" on June 6, 2023 at 16:15 (local time) in Room 104C, showcasing the latest innovative research and development achievements of Novamab in the field of respiratory diseases.
Novamab focuses on the research and development of sdAb drug development, takes root in the field of respiratory diseases, and continues to expand international cooperation. We sincerely invite you to come and interact at that time. Dr. Yakun Wan will carry out in-depth discussions on the research and development of inhaled macromolecule drug development in the field of respiratory diseases.
About the American Thoracic Society (ATS) Annual Congress
The American Thoracic Society (ATS) Annual Conference is the world's largest and most influential professional academic conference in the respiratory field. Every year, more than 14000 people from around the world participate in the latest research progress, breakthrough research, and cutting-edge science in respiratory care and sleep medicine. Many important international research results and discoveries are also released for the first time through the ATS Annual Conference. The American Thoracic Society (ATS) was established in 1905 and is the world's most authoritative respiratory academic organization, with over 16000 members. ATS is committed to improving global health by promoting research, patient care, and public health in fields such as lung disease, critical care, and sleep medicine.
About BIO International Convention
BIO International Convention was founded in 1993 and is the world's largest biotechnology industry event, gathering leading biopharmaceutical companies, investors, and partners from around the world. Many cooperation activities were held during the conference, providing a platform for promotion and display for enterprises, technology parks, and research and development institutions from various countries. The conference is hosted by the Biotechnology Innovation Organization (BIO) in the United States, which is the world's largest biotechnology industry association representing biotechnology companies, academic institutions, and related institutions.
Shanghai Novamab Biopharmaceuticals Co., Ltd. is an innovative biopharmaceutical enterprise committed to sdAb drug development and industrialization. Founded in October 2017, the company is located in Shanghai International Medical Park. It has Novamab has established the first and only sdAb development platform covering the full biopharmaceutical process in China. As of April 2023, we have nearly 90 employees, applied for nearly 70 patents with 25 authorized.
Novamab has independently created five core technology platforms: sdAb rapid screening platform, Pichia pastoris based CMC platform, biologcial drug inhalation platform, long-acting sdAb platform and bispecific sdAb platform. Each platform has unique leading technology, which makes it more competitive.The powerful paltform make it possible to rapidly bring the candidates to commercialization. The completion of the 500L GMP workshop for sdAb production using Pichia pastoris fills the industry gap in this field, which is extremely scarce and competitive.
Novamab has developed dozens of sdAb drugs, covering respiratory, anti-infection, ophthalmology and oncology. Currently, it has obtained three clinical approvals. LQ036 and LQ043 developed by Novamab have overturned the existing treatment methods for respiratory diseases, both of which are the world's first inhalable sdAb drug for their respective target. Phase I trials of LQ036 have been conducted in China and Australia, both demonstrating excellent safety and tolerability. The LQ036 IND files for COPD treatment will be submitted soon. In addition, phase I trial of LQ043 in China has completed the dosing of the third group of subjects. Most moderate to severe asthmatics would benefit from the LQ036 and LQ043 considering their mechanism of action.